Previous Page
11-08 :: August 2011
nanotimes
Companies Facts
that can be implemented in diverse carriers such as coatings, plastics or liquids. These agents can be antimicrobial substances, flagrances, flavours and materials for fire protection.
“Our unique technology basically allows us to incor- porate every substance into products of our clients so that they display the desired controlled long-term ef- fect,” says Hermann Schirra, CEO of the company.
http://www.sarastro-nanotec.com S
electa Biosciences, Inc., a biopharmaceutical company developing an entirely new class of
targeted vaccines and immunotherapies, announced that Science Applications International Corpora- tion (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle pro- duct for malaria. Under the terms of the award, the targeted Synthetic Vaccine Particle (tSVP™) vaccine for malaria will be developed by Selecta for testing in preclinical studies by SAIC collaborators. tSVP™ products are fully-integrated synthetic nanoparticle vaccines engineered to mimic the properties of na- tural pathogens to elicit a maximal immune response.
pire Corporation (NASDAQ: SPIR) reported reve- nues from continuing operations for the second-
quarter ended June 30, 2011 of $14.7 million, a 34% reduction from $22.3 million for the same quarter of 2010. Net income for the second-quarter of 2011 was $0.7 million, or $0.08 per share, compared to net income of $1.4 million, or $0.16 per share for
S
the second-quarter of 2010. Net income for the second-quarter of 2010 includes a net gain of $1.6 million or $0.19 per share from the Company’s Me- dical Products Business Unit which has been classi- fied as discontinued operations.
As of June 30, 2011, the Company had unrestricted cash and cash equivalents of $5.3 million.
Furthermore, Spire has been awarded a patent for its invention of a nanophotovoltaic (Nano-PV) device which, when applied to biological cells such as cancer, can control and/or limit their growth. The United States Patent and Trademark Office has issued Spire Corporation U.S. Patent No. 7,955,965 entitled “Nanophotovoltaic Devices.” Spire‘s inventi- on provides Nano-PV devices having sizes in a range of about 50nm to about 5µm, and a method for their fabrication. The devices functionalized to target spe- cific cells and then are selectively activated by light to generate an electrical charge to kill or interfere with cell growth.
Roger G. Little, Chairman, CEO, and co-inventor, said, “This being our third patent issued from our original invention, we have combined our understan- ding of photovoltaics with our experience in the bi- omedical field. We are excited to have received this patent and are enthusiastic that it makes an impact in medicine.”
tarpharma Holdings Limited (ASX:SPL, OTCQX: SPHRY) announced two important developments in relation to the commercialisation of its VivaGel®
-
45